Infliximab for patients with moderate to severely active ulcerative colitis: an updated meta-analysis of randomized controlled trials

Infliximab for patients with moderate to severely active ulcerative colitis: an updated meta-analysis of randomized controlled trials

Abstract Background and aims Ulcerative colitis (UC) is a serious inflammatory bowel disease with significant morbidity and mortality. Infliximab (IFX), a TNF-alpha antagonist, is recommended by the American Gastroenterological Association, but its clinical effectiveness and safety are based on limi...

Full description

Saved in:
Bibliographic Details
Main Authors: Min Zhang, Manman Li, Yangzan Ou, Qin Huang, Mingmin Leng, Xiangdong Yang, Tao Yang
Format: Article
Language:English
Published: BMC 2025-07-01
Series:BMC Gastroenterology
Subjects:
Ulcerative colitis
Infliximab
TNF-alpha antagonists
Evidence-based practice
Meta-analysis
Online Access:https://doi.org/10.1186/s12876-025-04065-w
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12876-025-04065-w

Similar Items